EXICURE, INC. Sublease Income
EXICURE, INC. (XCUR) reported Sublease Income of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2025-03-18
- EXICURE, INC. sublease income for the quarter ending 2024-12-31 was -$524.00K, a 241.24% decline year-over-year.
- EXICURE, INC. sublease income for the quarter ending 2024-09-30 was $178.00K, a 0.56% decline year-over-year.
- EXICURE, INC. sublease income for the quarter ending 2024-06-30 was $173.00K.
- EXICURE, INC. sublease income for the quarter ending 2024-03-31 was $173.00K.
- EXICURE, INC. sublease income for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- EXICURE, INC. sublease income for fiscal 2023 was $550.00K.
- EXICURE, INC. sublease income for fiscal 2022 was $0.00.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$524.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$346.00K derived: sum of 2 quarters · filed 2025-03-18 | -$173.00K derived: sum of 3 quarters · filed 2025-03-18 | $0.00 10-K · filed 2025-03-18 |
| 2024-09-30 | $178.00K 10-Q · filed 2024-11-14 | $351.00K derived: sum of 2 quarters · filed 2024-11-14 | $524.00K 10-Q · filed 2024-11-14 | $895.00K derived: sum of 4 quarters · filed 2025-03-18 |
| 2024-06-30 | $173.00K 10-Q · filed 2024-08-13 | $346.00K 10-Q · filed 2024-08-13 | $717.00K derived: sum of 3 quarters · filed 2025-03-18 | $896.00K derived: sum of 4 quarters · filed 2025-03-18 |
| 2024-03-31 | $173.00K 10-Q · filed 2024-06-17 | $544.00K derived: sum of 2 quarters · filed 2025-03-18 | $723.00K derived: sum of 3 quarters · filed 2025-03-18 | $723.00K derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-12-31 | $371.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $550.00K derived: sum of 2 quarters · filed 2025-03-18 | $550.00K derived: sum of 3 quarters · filed 2025-03-18 | $550.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $179.00K 10-Q · filed 2024-11-14 | $179.00K derived: sum of 2 quarters · filed 2024-11-14 | $179.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-06-17 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |